Sartorius Stedim lowers targets for 2024

(CercleFinance.com) - Sartorius Stedim Biotech has lowered its targets for 2024 on the occasion of its half-year publication, now forecasting a recurring EBITDA margin of 27% to 29% on sales at around the previous year's level.


"The life sciences industry continues to present a mixed picture, with no stable positive momentum", explains the Group, which is "deliberately taking a conservative and cautious approach to the outlook for the remainder of the year".

For its first half, the supplier to the pharmaceutical industry reported EPS down 59.3% to 1.08 euros, and recurring EBITDA down 6.8% to 387.3 million, corresponding to a margin down 1.5 points to 28.2%.

Sartorius Stedim Biotech posted sales of 1.37 billion euros, down slightly by 2% (-3.8% in organic terms), but taking into account advanced destocking by customers, its order intake rose by 10.4% to 1.26 billion.

Copyright (c) 2024 CercleFinance.com. All rights reserved.